A review of bevacizumab in the treatment of malignant pleural mesothelioma-Reference-Cited by-同舟云学术

A review of bevacizumab in the treatment of malignant pleural mesothelioma

Published:2017-12 Issue:28 Volume:13 Page:2537-2546
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Brosseau Solenn¹²,Assoun Sandra¹,Naltet Charles¹,Steinmetz Christelle³,Gounant Valérie¹,Zalcman Gérard¹²

Affiliation:

1. Department of Thoracic Oncology & CIC 1425/CLIP2 Paris-Nord, Bichat-Claude Bernard Hospital, APHP, Paris, France

2. University Paris-Diderot, Paris, France

3. Pharmacy Department, Bichat-Claude Bernard Hospital, APHP, Paris, 46, rue Henri Huchard, 75877 Paris Cedex 18, France

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis. Systemic chemotherapy is the primary treatment modality for the majority of patients. VEGF plays a key mitogen for MPM cells physiopathology. Bevacizumab, a monoclonal anti-VEGF antibody, was a rational approach to be tested in MPM. Based on the results of the Phase III IFCT-0701 mesothelioma avastin cisplatin pemetrexed study, cisplatin-pemetrexed-bevacizumab is now the accepted standard in France. The National Comprehensive Cancer Network guidelines have also included this combination as an option for standard front-line therapy. This review summarized the efficacy and safety data of bevacizumab in the treatment of patients with MPM.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2017-0307

Reference58 articles.

1. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

2. Prognostic factors in mesothelioma

3. Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 2005

4. Survival patterns in lung and pleural cancer in Europe 1999–2007: Results from the EUROCARE-5 study

5. Centers for Disease Control and Prevention. United States cancer statistics: an interactive cancer atlas (InCA). 1999–2013 Cancer incidence and mortality data. https://nccdcdcgov/DCPC_INCA/ (Accessed on 28/12/2016).

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case Report: Early diagnosis and bevacizumab-based chemotherapy for primary pericardial mesothelioma: a case with occupational asbestos exposure history;Frontiers in Cardiovascular Medicine;2023-11-20

2. VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial;Lung Cancer;2023-08

3. Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP;Targeted Oncology;2022-07

4. Silencing VDAC1 to Treat Mesothelioma Cancer: Tumor Reprograming and Altering Tumor Hallmarks;Biomolecules;2022-06-27

5. Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study;Thorax;2022-02-11